Predicting
Future Directions in Pulmonary Hypertension
The future of the diagnosis and treatment
of pulmonary arterial hypertension (PAH) is uncertain,
but it si much more promising than it was a decade
ago. Intravenous prostacyclin has changed the course
of this disease, and now one oral agent is approved
for use and clearly has an impact on PAH.
Our experts took aim in this issue
at what may come to be - in terms of understanding
the pathobiology, possible advances in therapy, and
new thinking on end points. So much of hte effort
driving new approaches to therapy stems from teh hope
that a yet-to-be discovered agent could unlock the
secret of reversing the disease process, addressing
the core issue of cell proliferation. How convenient
it would be if we could identify switches that mgiht
be turned off, thereby directing the vasculature to
reverse proliferation as we solve the riddle of restoring
vessel architecture and lung function. These topics
and much more are addressed in the Roundtable discussion.
I wish to thank two esteemed colleagues
who served as guest editors, Sean Gaine, MD, and Richard
N. Channick, MD, not only for organizing the Roundtable
but for recruiting the experts who contributed their
articles as well. Many of the advances foreseen by
our experts are still theoretical, yet some are tantalizingly
imminent. We need translational research to turn them
into clinical applications. Although work is progressing
swiftly to find a cure for PAH, this issue of Advances
in Pulmonary Hypertension seeks to "freeze"
the moving target, at least for the moment, or for
as long as is required to read these pages. After
that, the elusive target will move on, as will our
relentless effort to find and hit it.
Editor-in-Chief Ronald J. Oudiz, MD
Associate Professor of Medicine
UCLA School of Medicine
Director, Liu Center for Pulmonary Hypertension
Division of Cardiology
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California
Immediate Past Editor Vallerie V. McLaughlin, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension Program
University of Michigan Health System
Ann Arbor, Michigan
Editor-in-Chief Elect Richard Channick, MD
Professor of Clinical Medicine
Pulmonary and Critical Care Division
University of California, San Diego Medical Center
San Diego, California
Associate Editors Erika Berman Rosenzweig, MD
Assistant Professor of Pediatrics
Department of Pediatrics
Columbia College of Physicians and Surgeons
New York, New York
Robert Frantz, MD
Consultant in Cardiovascular
Diseases and Internal Medicine
Assistant Professor of Medicine
Mayo Clinic College of Medicine
Rochester, Minnesota
Srinivas Murali, MD, FACC
Professor of Medicine
Drexel University College of Medicine
Director, Division of Cardiovascular Medicine
Medical Director, Gerald McGinnis Cardiovascular Institute
Allegheny General Hospital
Pittsburgh, Pennsylvania
Publisher
Pulmonary Hypertension Association
Jack Stibbs, Board Chair
Rino Aldrighetti, President
Rachel Pokorney, Medical Services Associate Director
Publishing Staff
Stu Chapman, Executive Editor
Susan Chapman, Managing Editor
Heidi Green, Associate Editor
Gloria Catalano, Production Director
Michael McClain, Design Director
Editorial Offices
Advances in Pulmonary Hypertension
DataMedica
424 Dune Road Westhampton Beach, NY 11978
Tel: 631-288-7733
Fax: 631- 288-7744
Advances in Pulmonary Hypertension is circulated to
cardiologists, pulmonologists, rheumatologists and other selected
physicians by the Pulmonary Hypertension
Association
. The contents of the
articles are
independently determined ly the Editor
and the Editorial Advisory
Board.
Editorial Mission Advances in Pulmonary Hypertension is committed
to help physicians in their clinical decision
making by informing them of important
trends affecting their practice. Analyzing the
impact of new findings and covering current
information in the peer-reviewed literature,
Advances in Pulmonary Hypertension is published
four times a year. Advances in Pulmonary
Hypertension is the official journal
of the Pulmonary Hypertension Association.
Each article in this journal has been reviewed
and approved by members of the Editorial
Advisory Board.
Editorial Board
Todd Bull, MD
Division of Pulmonary Sciences and Critical Care Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Murali Chakinala, MD
Director, Pulmonary Hypertension Clinic
Washington University School of Medicine
St. Louis, Missouri
Kristin Highland, MD
Assistant Professor
Division of Pulmonary and Critical Care
Director, Pulmonary Hypertension Clinic
Medical University of South Carolina
Charleston, South Carolina
Jim Maloney, MD
Associate Professor of Pulmonary and Critical Care Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Ioana Preston, MD
Assistant Professor of Medicine
Tufts - New England Medical Center
Boston, Massachusetts
Zeenat Safdar, MD
Assistant Professor of Medicine
Department of Medicine, Pulmonary & Critical Care Section
Pulmonary Hypertension Center
Baylor College of Medicine
Houston, Texas
Rajan Saggar, MD
Assistant Professor
Division of Pulmonary and Critical Care
Medicine and Hospitalists
David Geffen School of Medicine
UCLA
Los Angeles, California
Robert Schilz, DO, PhD
Medical Director of Lung
Transplantation and Pulmonary Vascular Disease
University Hospital of Cleveland
Case Western Reserve University
Cleveland, Ohio
Francisco Soto, MD, MS
Assistant Professor
Director, Pulmonary Hypertension Program
Medical College of Wisconsin
Milwaukee, Wisconsin
Roxana Sulica, MD
Assistant Professor of Medicine
Albert Einstein College of Medicine
Director, Beth Israel Pulmonary Hypertension Program
Beth Israel Medical Center
New York, New York
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
Predicting
Future Directions in Pulmonary Hypertension
